SCHEMBL4324167

SCHEMBL4324167

Clc1cccc(-c2cc(-c3cccnc3)no2)c1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.62
TP53 P04637 2/20 0.62
POLB P06746 1/20 0.62
CYP2C9 P11712 5/20 0.51
CYP2C19 P33261 5/20 0.51
NPC1 O15118 4/20 0.51
RAB9A P51151 4/20 0.51
CYP2E1 P05181 1/20 0.51
CYP2A6 P11509 1/20 0.51
CYP2B6 P20813 1/20 0.51
CYP1A2 P05177 4/20 0.50
CYP3A4 P08684 4/20 0.50
CYP2D6 P10635 3/20 0.50
MEN1 O00255 1/20 0.48
ALDH1A1 P00352 1/20 0.48
KMT2A Q03164 1/20 0.48
NPY5R Q15761 1/20 0.48
NOTUM Q6P988 1/20 0.48
ABL1 P00519 1/20 0.47
BCR P11274 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4316607 0.87 NPC1 (0.69) MAPTTP53POLBCYP2C9CYP2C19
SCHEMBL4331569 0.87 NPC1 (0.53) MAPTTP53POLBNPC1RAB9A
SCHEMBL4318440 0.86 CYP3A4 (0.62) TP53CYP2C9CYP2C19NPC1RAB9A
SCHEMBL4316645 0.85 CYP2C9 (0.53) MAPTTP53POLBCYP2C9CYP2C19
SCHEMBL4331772 0.84 CYP2C9 (0.52) MAPTTP53POLBCYP2C9CYP2C19
SCHEMBL4315720 0.83 MAPT (0.50) MAPTTP53POLBNPC1RAB9A
SCHEMBL4322525 0.83 RAB9A (0.70) MAPTTP53CYP2C9CYP2C19NPC1
SCHEMBL17084388 0.83 NPC1 (0.73) MAPTTP53CYP2C9CYP2C19NPC1
SCHEMBL4325908 0.82 CYP2C9 (0.65) TP53CYP2C9CYP2C19NPC1RAB9A
SCHEMBL4322830 0.82 MEN1 (0.61) MAPTTP53POLBCYP2C9CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090306096-A1 Novel Isoxazoles and Methods of Use Thereof ABBOTT LABORATORIES (US) 2009-12-10 US claimed
WO-2009149135-A1 BIS (HETERO ) ARYL SUBSTITUTED ISOXAZOLES FOR USE AS NEURONAL NICOTINIC RECEPTOR MODULATORS ABBOTT LABORATORIES (US) 2009-12-10 WO claimed
US-8383658-B2 Isoxazole based neuronal nicotinic receptor ligands and methods of use ABBOTT LABORATORIES (US) 2013-02-26 US disclosed
WO-2009149135-A1 BIS (HETERO ) ARYL SUBSTITUTED ISOXAZOLES FOR USE AS NEURONAL NICOTINIC RECEPTOR MODULATORS ABBOTT LABORATORIES (US) 2009-12-10 WO disclosed
US-20090306096-A1 Novel Isoxazoles and Methods of Use Thereof ABBOTT LABORATORIES (US) 2009-12-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090306096-A1 Novel Isoxazoles and Methods of Use Thereof XDH, PRDX5, CYP4X1 MAPT 2896/4885TP53 4606/4885POLB 1349/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.